Efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients

Table 1 Comparison of clinical data between the two groups, n %

Clinical information	S-1 group (n = 47)	Gemcitabine group (n = 47)	χ2/t	P value
Gender			0.092	0.761
Male	27 (57.45)	26 (55.32)
Female	20 (42.55)	21 (44.68)
Types			0.361	0.548
Squamous carcinoma	23 (48.94)	25 (53.19)
Adenocarcinoma	24 (51.06)	22 (46.81)
TNM staging			0.130	0.719
Phase IIIB	36 (76.60)	37 (78.72)
Phase IV	11 (23.40)	10 (21.28)
Age (yr)	56.95 (4.15)	56.17 (4.01)	0.927	0.357
Weight (kg)	53.94 (3.52)	54.09 (3.61)	0.204	0.839
BMI (kg/m2)	21.14 (3.21)	21.51 (3.45)	0.538	0.592

TNM: Tumor-node-metastasis; BMI: Body mass index.